NY-SHISEIDO
7.8.2019 16:59:06 CEST | Business Wire | Press release
Shiseido Company, Limited (“Shiseido”), a leading global beauty company, and Tory Burch LLC (“Tory Burch”) today announced that they have entered into a long-term partnership agreement under which Shiseido will have the exclusive worldwide license to develop, market, and distribute Tory Burch beauty brands. The agreement will be effective as of January 1, 2020. Tory Burch’s beauty license will be managed by Shiseido Group’s Americas region headquartered in New York City.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190807005529/en/
Tory Burch is an American lifestyle brand that embodies the personal style, global mindset and aesthetic of its Executive Chairman and Chief Creative Officer, Tory Burch, a modern and dynamic entrepreneur who launched her company in 2004. Today, the collection includes ready-to-wear, shoes, handbags, accessories, watches, home and fragrance. The first Tory Burch fragrance products were launched in 2013, and are currently available in Tory Burch boutiques and luxury retailers around the world.
Through this partnership, Shiseido will provide Tory Burch with a global platform and dedicated resources to elevate the Tory Burch beauty business, and to cultivate and capture opportunities as a multi-platform, global lifestyle beauty brand. For Shiseido, this partnership will expand its global fragrance portfolio, and create opportunities for collaboration across Shiseido Group and the company’s Centers of Excellence in Fragrance, Makeup, Skincare and Digital, as well as the company’s Technology Acceleration Hub.
Masahiko Uotani, President and CEO of Shiseido, said, “Shiseido is on an exciting journey to achieve its long-term mission of BEAUTY INNOVATIONS FOR A BETTER WORLD, and we are honored to welcome Tory and the Tory Burch brand to the Shiseido family and pursue this mission together as partners. Tory Burch is a truly luxurious lifestyle brand with a clear identity and strong commitment to its values – exactly the type of innovative partner we seek to enhance our portfolio as we continue to find new ways of cultivating consumer engagement and bringing value to our business and to society. Shiseido is dedicated to creating value for all of its partners and we are excited to share the benefits of Shiseido’s platform, R&D resources, technology portfolio and Centers of Excellence with the Tory Burch brand to help maximize its significant potential and opportunities for growth and development.”
Tory Burch, Executive Chairman and Chief Creative Officer, commented: “We are thrilled to be partnering with Shiseido, a company I have always admired for its rich history, unparalleled products and dedication to innovation. There are great synergies between our companies including a deep respect and connection to our customers, a passion to support women’s empowerment and an aligned long-term strategic vision. We could not be more excited to build a global lifestyle fragrance and beauty concept in partnership with Shiseido, a realization of a long-time dream.”
Pierre-Yves Roussel, CEO of Tory Burch, added: “We are proud of what we have accomplished with our family of fragrances to date and we are extremely honored to move the business forward with this new strategic partnership. Shiseido is an influential global leader setting the highest standard of excellence in the industry. We look forward to working with them to drive the next phase of development and expansion for Tory Burch Beauty.”
Marc Rey, CEO of Shiseido Americas and Shiseido Chief Growth Officer, said, “Tory Burch is a powerhouse fashion brand that shares many of the same values as Shiseido, and we’re thrilled to be in partnership together. There’s a tremendous opportunity to grow the Tory Burch business, and Shiseido is honored to provide Tory Burch with the resources to do so. By combining Tory’s beloved vision and the brand’s future-forward approach to digital, with Shiseido’s global platform and expertise in beauty and technology, this partnership has the ability to connect even more deeply with consumers and unleash the brand’s full potential. We are especially proud to partner with Tory, who sets an example for us all as a visionary, entrepreneur and an advocate for women’s empowerment, and we look forward to working closely with the broader team.”
About Shiseido Company, Limited
Shiseido was founded in 1872 as the first Western-style pharmacy in Japan. The business gradually evolved into a cosmetics company, offering people the most advanced technology and the finest aesthetics available in the East or the West. Now, known globally as the premier cosmetics company with roots in Japan the name Shiseido has come to represent the world’s highest standard of quality in beauty. Shiseido’s global selection of skincare, makeup and fragrance includes a high-performance category for special skincare, and a brightening line. Shiseido offers products for professional beauty salons and hairdressers, as well as body care, suncare and a skincare line for men. Fiercely contemporary and innovative with over 140 years in business, the Shiseido group brands are now sold in over 120 countries. For more information, please visit http://www.shiseidogroup.com/ .
About Tory Burch
Tory Burch is an American lifestyle brand that inspires people around the world to live in full color with character, beauty and confidence. Launched in February 2004, the collection includes multiple categories ranging from footwear and handbags, to ready-to-wear and home embodying the personal style of the company’s Executive Chairman and Chief Creative Officer, Tory Burch. There are more than 250 Tory Burch boutiques across North America, Europe, the Middle East, Latin America, Asia and Australia, and the collection is available at over 3,000 department and specialty stores worldwide and toryburch.com. The brand’s dedication to helping women fearlessly follow their dreams is reflected in the work of the Tory Burch Foundation, which advances women’s empowerment and entrepreneurship in the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005529/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom